Campylobacteriosis is the most common cause of bacterial foodborne illness in the European Union and the United States. Infection with Campylobacter spp. is frequently associated with different sequelae including neuropathies and reactive arthritis. Diagnosis is mainly by bacterial culturing which is time consuming, expensive, and not well suited for diagnosing sequelae or identifying infections from stool samples with nonviable bacteria. Serologic assays, in particular ELISAs, are well suited for this purpose, but, at present, there is no international consensus on antibody assays for human campylobacteriosis. In an extensive literature review, 19 studies validating such assays were identified of which 13 were more than 10 years old. We conclude that the best validated of these assays are developed and used in-house for research purposes rather than for routine diagnostics. Considering the burden of disease and potential long-term severity of Campylobacter infections, developing a standardized, commercially available antibody assay could be of great benefit for diagnostic and surveillance purposes worldwide.
Copyright © 2012 Elsevier Inc. All rights reserved.